183 related articles for article (PubMed ID: 14506059)
21. Effects of several antifungal drug combinations against clinical and environmental isolates of Cryptococcus neoformans from China.
Zhu LP; Gil-Lamaignere C; Müller FM
Mycoses; 2004 Aug; 47(7):319-25. PubMed ID: 15310338
[TBL] [Abstract][Full Text] [Related]
22. In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole.
Yildiran ST; Saracli MA; Fothergill AW; Rinaldi MG
Eur J Clin Microbiol Infect Dis; 2000 Apr; 19(4):317-9. PubMed ID: 10834825
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
[TBL] [Abstract][Full Text] [Related]
24. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
[TBL] [Abstract][Full Text] [Related]
25. In vitro combination between antifungals and diphenyl diselenide against Cryptococcus species.
Rossato L; Loreto ES; Venturini TP; de Azevedo MI; Al-Hatmi AMS; Santurio JM; Alves SH
Mycoses; 2019 Jun; 62(6):508-512. PubMed ID: 30776159
[TBL] [Abstract][Full Text] [Related]
26. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
[TBL] [Abstract][Full Text] [Related]
27. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
Selb R; Fuchs V; Graf B; Hamprecht A; Hogardt M; Sedlacek L; Schwarz R; Idelevich EA; Becker SL; Held J; Küpper-Tetzel CP; McCormick-Smith I; Heckmann D; Gerkrath J; Han CO; Wilmes D; Rickerts V
Int J Med Microbiol; 2019 Sep; 309(6):151336. PubMed ID: 31444102
[TBL] [Abstract][Full Text] [Related]
28. [Genotypes and in vitro antifungal susceptibility of Cryptococcus isolates in Sichuan Province].
Lei Y; Xiao YL; He C; Zhang CY; Xie Y; Kang M
Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Jan; 46(1):82-6. PubMed ID: 25807801
[TBL] [Abstract][Full Text] [Related]
29. Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC.
Fromtling RA; Abruzzo GK; Bulmer GS
Mycopathologia; 1986 Apr; 94(1):27-30. PubMed ID: 3014339
[TBL] [Abstract][Full Text] [Related]
30. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
31. In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans.
Ghannoum MA; Fu Y; Ibrahim AS; Mortara LA; Shafiq MC; Edwards JE; Criddle RS
Antimicrob Agents Chemother; 1995 Nov; 39(11):2459-65. PubMed ID: 8585726
[TBL] [Abstract][Full Text] [Related]
32. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates.
Nguyen MH; Yu CY
Antimicrob Agents Chemother; 1998 Feb; 42(2):471-2. PubMed ID: 9527812
[TBL] [Abstract][Full Text] [Related]
33. In vitro susceptibility of Cryptococcus neoformans isolates to five antifungal drugs using a colorimetric system and the reference microbroth method.
López-Jodra O; Torres-Rodríguez JM; Méndez-Vásquez R; Ribas-Forcadell E; Morera-López Y; Baró-Tomás T; Alia-Aponte C
J Antimicrob Chemother; 2000 May; 45(5):645-9. PubMed ID: 10797087
[TBL] [Abstract][Full Text] [Related]
34. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp.
Mosquera J; Sharp A; Moore CB; Warn PA; Denning DW
J Antimicrob Chemother; 2002 Aug; 50(2):189-94. PubMed ID: 12161398
[TBL] [Abstract][Full Text] [Related]
35. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.
Kantarcioğlu AS; Boekhout T; Yücel A; Altas K
Med Mycol; 2009 Mar; 47(2):169-76. PubMed ID: 18654925
[TBL] [Abstract][Full Text] [Related]
37. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
Franzot SP; Casadevall A
Antimicrob Agents Chemother; 1997 Feb; 41(2):331-6. PubMed ID: 9021188
[TBL] [Abstract][Full Text] [Related]
38. Antifungal susceptibility of clinical and environmental isolates of Cryptococcus neoformans to four antifungal drugs determined by two techniques.
Moraes EM; Prímola NS; Hamdan JS
Mycoses; 2003 Jun; 46(5-6):164-8. PubMed ID: 12801356
[TBL] [Abstract][Full Text] [Related]
39. In vitro susceptibility of Cryptococcus neoformans isolates from patients with acquired immunodeficiency syndrome.
Poon M; Cronin DC; Wormser GP; Bottone EJ
Arch Pathol Lab Med; 1988 Feb; 112(2):161-2. PubMed ID: 3276290
[TBL] [Abstract][Full Text] [Related]
40. In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
Illnait-Zaragozi MT; Martínez GF; Curfs-Breuker I; Fernández CM; Boekhout T; Meis JF
Antimicrob Agents Chemother; 2008 Apr; 52(4):1580-2. PubMed ID: 18212095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
